53
Recently, the first traceable drug, Abilify MyCite, was licensed by the US Food and Drug Administration (FDA) to determine when it was absorbed into the body. The drug, developed by the drug company Otksuka, uses special sensors to monitor its condition.
The new drug sends information about the body's absorption to the wearable device
Drug sensors send the required information to a wearable device and then this information is sent to the smartphone for display. In this way, the user is informed about the time of drug absorption through a special app. Also, with the help of sensors, doctors can find out information related to drug absorption online.
It should be noted that the sensors used in the drug were first licensed by the US Food and Drug Administration in 2012. It is used to treat schizophrenia, bipolar disorder, and as an adjunct to adult depression.
